Published in Am J Med on April 01, 1992
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol (2005) 2.08
Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol (2010) 1.67
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol (2013) 1.20
Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review. Eur J Pediatr (2009) 1.19
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation (2013) 0.92
Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol (2008) 0.91
Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant (2011) 0.90
Educational paper: the podocytopathies. Eur J Pediatr (2012) 0.88
Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol (2003) 0.87
Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr Nephrol (1995) 0.84
Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol (2013) 0.81
Hypertension after renal transplantation. Pediatr Nephrol (2007) 0.81
Recurrent focal segmental glomerulosclerosis in renal allograft recipients: role of human leukocyte antigen mismatching and other clinical variables. Int J Nephrol (2011) 0.79
A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol (2013) 0.78
Glomerular permselectivity in proteinuric patients after kidney transplantation. J Clin Invest (1995) 0.78
Complete remission of post-transplant FSGS recurrence by long-term plasmapheresis. Pediatr Nephrol (2005) 0.78
Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs (2010) 0.78
Focal segmental glomerulosclerosis in renal allografts: Is it possible to diagnose the etiology? Indian J Nephrol (2015) 0.78
Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol (2016) 0.77
The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol (2016) 0.77
Recent advances in understanding and treating nephrotic syndrome. F1000Res (2017) 0.75
Remission of post-transplant focal segmental glomerulosclerosis with angiotensin receptor blockers. Indian J Nephrol (2017) 0.75
The Impact of Histologic Variants on FSGS Outcomes. Int Sch Res Notices (2014) 0.75
Focal Segmental Glomerulosclerosis in a Patient with Ambiguous Genitalia: A Diagnostic Dilemma. Perm J (2017) 0.75
Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target. Int J Mol Sci (2014) 0.75
Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis. J Transplant (2015) 0.75
Treatment of Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft: A Report of Two Cases. Case Rep Nephrol Dial (2016) 0.75
Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. Biomed Res Int (2017) 0.75
Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 4.41
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Tolerance versus immunosuppression: a perspective. Am J Transplant (2008) 2.71
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 2.46
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant (2007) 2.46
Electron Microscopic Observations on Councilman-Like Acidophilic Bodies and Other Forms of Acidophilic Changes in Human Liver Cells. Am J Pathol (1965) 2.42
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.78
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 1.52
The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med (1989) 1.49
Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg (1980) 1.45
A ten year experience with cadaver kidney preservation using cryoprecipitated plasma. Am J Surg (1978) 1.44
The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation (1995) 1.43
Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant (2012) 1.42
Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation (1998) 1.35
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant (2008) 1.33
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant (2010) 1.31
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation (1999) 1.29
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27
Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation (1999) 1.27
Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant (2013) 1.23
Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis (1994) 1.18
A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation (1985) 1.17
Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant (2007) 1.05
FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. Transplant Proc (1997) 1.03
Polyribosomes in Azotobacter vinelandii. I. Isolation, characterization and distribution of ribosomes, polyribosomes and subunits in logarithmically growing azotobacter. Biochim Biophys Acta (1968) 1.00
The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med (1980) 1.00
Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival. N Engl J Med (1978) 0.97
Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci (2005) 0.97
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant (2009) 0.95
Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects. Transplantation (1983) 0.93
Ultrastructural observations on renal glycogen in normal and pathologic human kidneys. Lab Invest (1966) 0.92
The influence of presensitization on graft survival rate. Surgery (1977) 0.91
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation (2001) 0.91
Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months. Transplant Proc (1986) 0.90
Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation (1992) 0.90
Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis (1986) 0.90
Improved outcome following renal transplantation with reduction in the immunosuppression therapy for rejection episodes. Am J Med (1980) 0.90
Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc (1995) 0.89
Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. Kidney Int (2003) 0.89
Update of the University of California at San Francisco experience with donor-specific blood transfusions. Transplant Proc (1982) 0.88
Fine structure of normal human juxtaglomerular cells. I. General structure and intercellular relationships. Am J Pathol (1966) 0.88
Donor selection limits use of living-related liver transplantation. Hepatology (1995) 0.88
Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis (1967) 0.88
1,500 renal transplants at one center: evolution of a strategy for optimal success. Am J Surg (1981) 0.87
Diabetic management by insulin infusion during major surgery. Am J Surg (1979) 0.87
Gluten-induced enteropathy. Osteomalacia as its principal manifestation. Arch Intern Med (1974) 0.87
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation (1996) 0.86
Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation (2000) 0.85
Do blood transfusions enhance the possibility of a compatible transplant? Transplantation (1979) 0.85
Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys--long term experiences with 40 transplants. Transplantation (1997) 0.83
De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation (1983) 0.82
Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int (1982) 0.82
Combined use of dopamine and prostaglandin A1 in patients with acute renal failure and hepatorenal syndrome. Prostaglandins (1978) 0.82
Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantation. Transplantation (2003) 0.82
Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation (1989) 0.82
Incidence, characteristics, and outcome of recipients sensitized after donor-specific blood transfusions. Transplantation (1981) 0.82
Parathyroid and bone response of the diabetic patient to uremia. Kidney Int (1984) 0.82
Pretreatment with donor-specific blood transfusions in related recipients with high MLC. Transplant Proc (1981) 0.82
Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation (2001) 0.81
Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol. Transplant Proc (1991) 0.81
Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function. Am J Med (1982) 0.81
The clinical course of IgA-nephropathy and Henoch-Schönlein purpura following renal transplantation. Transplantation (1986) 0.81
Hepatic Injury following halothane, enflurane, and isoflurane anesthesia in rats. Anesthesiology (1982) 0.81
Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes (1987) 0.80
Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy (1997) 0.80
Recurrent systemic lupus erythematosus involving renal allografts. Ann Intern Med (1981) 0.80
Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant (2000) 0.80
Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. J Am Coll Cardiol (1988) 0.80
Cyclosporin A and prednisolone: an additive inhibitory effect of cell proliferation and interleukin-2 production. Transplant Proc (1989) 0.80
Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation (1996) 0.80
The transplanted kidney as a source of hepatitis B infection. Ann Intern Med (1979) 0.80
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol (2006) 0.80
Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. Transplant Proc (1999) 0.79
Herpetic esophagitis causing intractable hiccups. Ann Intern Med (1993) 0.79
Anaesthetic management of children with type II and III Gaucher disease. Minerva Pediatr (1997) 0.79
Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc (1983) 0.79
Donor-specific blood transfusions versus cyclosporine--the DST story. Transplant Proc (1987) 0.78
A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant (2000) 0.78
Cyclosporine-induced chronic nephropathy in human recipients of cardiac allografts. Transplant Proc (1985) 0.78
Prevention of prednisone-induced negative nitrogen balance. Effect of dietary modification on urea generation rate in patients on hemodialysis receiving high-dose glucocorticoids. Ann Intern Med (1981) 0.78
Microtubule aggregates in a clival chordoma. Arch Pathol Lab Med (1993) 0.78